Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

GENINCA · Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer

FP7Status: CLOSED1 January 200830 June 2011EU funding €2,995,569

GENINCA will address two tumor entities, for which we have good access to pre-malignant lesions and in which genomic instability is a common feature: colorectal and liver cancer. Colorectal cancer amounts to 13.2% of all incident cases of cancer, the second most common form of cancer, surpassed only by lung cancer (13.3%). Liver cancer accounts for about 2% of total cancers, however, the most common liver cancer, i.e. hepatocellular carcinoma (HCC), is among the most lethal form of cancer, and its incidence in Europe has been steadily rising over the last few decades. GENINCA represents a collaborative study of 8 academic and 3 industrial partners from 5 European countries. GENINCA will focus on exploring pre-cancerous and cancer lesions of the two aforementioned tumor entities and their respective microenvironment. As the recent identification of human colon-cancer initiating cells by one of our academic consortium members paves the way for completely new strategies for studying mechanisms of tumorigenesis, a particular focus of this grant proposal will be the detailed characterization of these cancer initiating stem cells. At present, it is still a matter of debate which genomic changes are already present in precursor lesions and whether these lesions already show genetic instability. We will therefore address the occurrence of genomic instability and explore their underlying mechanisms especially in pre-cancerous and early cancer lesions. This will be greatly facilitated by in vivo endomicroscopy approaches, sophisticated animal models and large-scale genomic and proteomic analyses. Furthermore, we will include an in-depth analysis of the corresponding microenvironment. As this represents a translational research effort, we expect to identify markers for novel therapeutic and/or preventative strategies, as well as to facilitate tumor diagnosis, prognosis, and monitoring.

Consortium · 14 organisations

coordinator

MEDIZINISCHE UNIVERSITAT GRAZ

AT · €264,483

participant

ORIDIS BIOMARKERS GMBH

AT · €26,227

participant

CANCER RESEARCH UK LBG

UK

participant

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

FR · €276,525

participant

JOHANNES GUTENBERG-UNIVERSITAT MAINZ

DE · €89,061

participant

UNIVERSITAET ULM

DE · €322,132

participant

ISTITUTO SUPERIORE DI SANITA

IT · €202,500

participant

ORIDIS BIOMED FORSCHUNGS-UND ENTWICKLUNGS GMBH

AT · €329,481

participant

BIOLUTION GMBH

AT · €267,192

participant

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF

DE · €247,200

participant

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

UK · €316,027

participant

UNIVERSITATSKLINIKUM ERLANGEN

DE · €134,139

participant

MOSAIQUES DIAGNOSTICS GMBH

DE · €244,002

participant

IFOM-ISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLARE ETS

IT · €276,600

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.